This panel examines patient selection, surgical indications, and whether current practice aligns with the evolving evidence base — drawing on perspectives from both public and private hospital settings.
Key Takeaways:
• Understanding how advanced GLP-1s and dual/triple agonists achieve superior weight loss and metabolic improvements, including their effects on appetite regulation, insulin sensitivity, and cardiovascular benefits beyond traditional interventions.
• Where current clinical habits across public and private settings diverge from the latest evidence, and what it will take to close that gap.
Check out the incredible speaker line-up to see who will be joining Michael.
Download The Latest Agenda